GlassScriptPhysician profile
James D Robinson
NPI 1649237835
$2,344.28
in general payments reported to CMS, 2019-2025
29 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $206 · 2021: $13.83 · 2022: $11.80 · 2023: $96.15 · 2024: $685 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.21 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $321.46 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.85 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $206.96 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $198.68 | 2019-2020 | |
| Novo Nordisk INC | $156.69 | 2019-2024 | Wegovy |
| Inspire Medical Systems, INC. | $136.16 | 2025 | Inspire |
| Astellas Pharma US INC | $120.06 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $93.47 | 2024 | Auvelity |
| Lilly USA, LLC | $88.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $88.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $71.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.79 | 2019-2025 | Jardiance |
| Abbvie INC. | $63.53 | 2023-2024 | Vraylar |
| Merck Sharp & Dohme LLC | $47.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $43.53 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $42.50 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $42.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $37.38 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.23 | 2024-2025 | Caplyta |
| Genentech USA, INC. | $33.24 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.09 | 2023-2024 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $28.44 | 2019-2020 | |
| Amarin Pharma, INC. | $27.42 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $26.50 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $23.78 | 2019 | |
| Allergan, INC. | $23.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $17.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.30 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.